On April 15, 2021 Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, reported that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit (Press release, Kaleido Biosciences, APR 15, 2021, View Source [SID1234578086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the fireside chat will be made available that morning as of 8am EDT on the Investors & Media section of Kaleido’s website at View Source An archived replay will be available for 90 days following the event.